Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
04/30/19
DUBLIN, Ireland , April 30, 2019 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced that it will release financial results for the period ended March 31, 2019 and provide a business update after market close on Tuesday, May 7, 2019
04/02/19
DUBLIN, Ireland , April 2, 2019 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in a fireside chat at the 18 th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 , at 9:20 a.m. ET .
03/25/19
Presentation to highlight data for novel, once-daily norepinephrine reuptake inhibitor in patients with neurogenic orthostatic hypotension 20-week data support previously-announced clinical observations after four weeks of treatment DUBLIN , March 25, 2019 /PRNewswire/ --  Theravance Biopharma,
03/12/19
Induction and maintenance portions of study to evaluate gut-selective pan-JAK inhibitor in patients with moderately to severely active ulcerative colitis DUBLIN , March 12, 2019 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced
02/26/19
YUPELRI™ (revefenacin) inhalation solution product launch progressing in partnership with Mylan Ampreloxetine and TD-1473 late-stage clinical programs advancing DUBLIN , Feb. 26, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (" Theravance Biopharma " or the "Company") (NASDAQ: TBPH) today
02/21/19
DUBLIN , Feb. 21, 2019 /PRNewswire/ --   Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in a fireside chat at the 8 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 , at 9:00 a.m. ET .
02/19/19
In the news release, Theravance Biopharma to Report Fourth Quarter and Full Year 2018 Financial Results on February 26 , issued 19-Feb-2019 by Theravance Biopharma, Inc. over PR Newswire, we are advised by the company that date in the second paragraph, first sentence, should read " February 26,
01/28/19
Study to evaluate novel, once-daily ampreloxetine in symptomatic nOH patients with primary autonomic failure, including multiple system atrophy, Parkinson's disease, and pure autonomic failure DUBLIN , Jan. 28, 2019 /PRNewswire/ --  Theravance Biopharma, Inc.
01/07/19
DUBLIN , Jan. 7, 2019 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced a reduction in workforce to align with its focus on continued execution of key strategic programs, and advancement of selected late-stage research programs
12/04/18
DUBLIN , Dec. 4, 2018 /PRNewswire/ --  Theravance Biopharma, Inc.  (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") will host an R&D Day from 12:00 p.m. ET to 3:00 p.m. ET on Wednesday, December 12, 2018 , in New York City . Theravance Biopharma management and R&D teams will provide an